Abstract
There is an urgent need for new drugs to treat tuberculosis. During the last forty years the only drugs to have been developed are variations on existing ones, but new drug candidates must offer improvements over existing agents. In particular, we require new drugs having novel mechanisms of action that are active against drug-resistant strains and also kill persistent bacilli, thus shortening the length of chemotherapy. Recent advances in our understanding of the biology of Mycobacterium tuberculosis, in particularly the availability of the genome sequence coupled with development of new genetic tools, have greatly contributed to the discovery of potential drug targets for new antituberculars. However, although many potential new drug targets have been identified, greater effort is required in target validation to show properly that they are essential for bacterial growth and survival. In this review, the current drug development pipeline and the strategies employed to identify and validate novel tuberculosis drug targets are presented.
Keywords: Tuberculosis, drug discovery, essential gene, target validation
Current Molecular Medicine
Title: Current Strategies for Identifying and Validating Targets for New Treatment-Shortening Drugs for TB
Volume: 7 Issue: 3
Author(s): Kerstin J. Williams and Ken Duncan
Affiliation:
Keywords: Tuberculosis, drug discovery, essential gene, target validation
Abstract: There is an urgent need for new drugs to treat tuberculosis. During the last forty years the only drugs to have been developed are variations on existing ones, but new drug candidates must offer improvements over existing agents. In particular, we require new drugs having novel mechanisms of action that are active against drug-resistant strains and also kill persistent bacilli, thus shortening the length of chemotherapy. Recent advances in our understanding of the biology of Mycobacterium tuberculosis, in particularly the availability of the genome sequence coupled with development of new genetic tools, have greatly contributed to the discovery of potential drug targets for new antituberculars. However, although many potential new drug targets have been identified, greater effort is required in target validation to show properly that they are essential for bacterial growth and survival. In this review, the current drug development pipeline and the strategies employed to identify and validate novel tuberculosis drug targets are presented.
Export Options
About this article
Cite this article as:
Williams J. Kerstin and Duncan Ken, Current Strategies for Identifying and Validating Targets for New Treatment-Shortening Drugs for TB, Current Molecular Medicine 2007; 7 (3) . https://dx.doi.org/10.2174/156652407780598575
DOI https://dx.doi.org/10.2174/156652407780598575 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Developments in the Chemistry and Biology of G-Quadruplexes with Reference to the DNA Groove Binders
Current Pharmaceutical Design The Recent Electrochemical Biosensor Technologies for Monitoring of Nucleic Acid Hybridization
Current Analytical Chemistry Radiological Presentation of H1N1 Influenza in the 2017 Outbreak in India and Correlation with Patient Outcome
Current Respiratory Medicine Reviews Tumour Necrosis Factor α Gene Promoter and its Role in Rheumatoid Arthritis Outcome and Pharmacogenetics
Current Pharmacogenomics Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Preface:
Current Topics in Medicinal Chemistry Nanoparticles for Cancer Targeting: Current and Future Directions
Current Drug Delivery Computational Insight into the Binding Mechanism of Pyrazinoic Acid to RpsA Protein
Current Chinese Science The First Kinetic Enzymatic Resolution of Methyl Ester of C75
Letters in Organic Chemistry Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry Fracture Risk Associated with Use of Antibiotics
Current Drug Safety Editorial (Hot Topic: Computer-Aided Drug Design, Synthesis and Evaluation of New Anti-Cancer Drugs)
Current Topics in Medicinal Chemistry Effect of Polarization of Ligand Charges and Estimation of MM/GBSA Binding Free Energies of Some Pyrazolo[3,4-d]pyrimidine Inhibitors of Mycobacterium Tuberculosis in View of Experimental Results
Current Enzyme Inhibition Xenicane Natural Products: Biological Activity and Total Synthesis
Current Pharmaceutical Design Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease?
Current Medicinal Chemistry Biomarkers in the Diagnosis of Ventilator-Associated Pneumonia
Current Respiratory Medicine Reviews An Interventional Pulmonologist’s Tool: Endobronchial Ultrasound- Guided Transbronchial Needle Aspiration (EBUS-TBNA) in Thoracic Disease — An Update
Current Respiratory Medicine Reviews Ontologies of Drug Discovery and Design for Neurology, Cardiology and Oncology
Current Pharmaceutical Design Fatty Acid Intakes and Coronary Heart Disease Mortality in Japan: NIPPON DATA90, 1990-2005
Current Nutrition & Food Science Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology